Aspen Pharmacare Holdings LimitedJSE: APN

APN: Revenue up 10% to R44.7bn, EBITDA up 1%, and portfolio de-risked by key acquisitions

· Issued by Aspen Pharmacare Holdings Limited

Revenue rose 10% to R44.7 billion with strong H2 performance, while normalised EBITDA grew 1% and NHEPS remained flat. Strategic acquisitions de-risked the portfolio, Manufacturing delivered above guidance, and a robust sustainability strategy was formalised.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis